Leonard S. Schleifer - Aug 6, 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
President & CEO, Director
Signature
/s/**Leonard S. Schleifer
Stock symbol
REGN
Transactions as of
Aug 6, 2021
Transactions value $
-$118,049,598
Form type
4
Date filed
8/10/2021, 05:05 PM
Next filing
Aug 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $12.5M +240K +72% $52.03 573K Aug 6, 2021 Direct F1
transaction REGN Common Stock Tax liability -$83.3M -137K -23.92% $607.51 436K Aug 6, 2021 Direct F1
transaction REGN Common Stock Options Exercise $8.32M +160K +36.68% $52.03 596K Aug 6, 2021 Direct F1
transaction REGN Common Stock Tax liability -$55.5M -91.4K -15.34% $607.51 505K Aug 6, 2021 Direct F1
transaction REGN Common Stock Gift $0 +41.2K $0.00 41.2K May 19, 2021 By Trust F2
transaction REGN Common Stock Gift $0 -41.2K -100% $0.00* 0 May 19, 2021 by 2019 GRAT
holding REGN Common Stock 200K Aug 6, 2021 2021 GRAT
holding REGN Common Stock 5.87K Aug 6, 2021 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -240K -60% $0.00 160K Aug 6, 2021 Common Stock 240K $52.03 Direct F1, F3
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -160K -100% $0.00* 0 Aug 6, 2021 Common Stock 160K $52.03 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.
F3 With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 160,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant.